ArticleCureus2026
Clinical Outcomes of Abrocitinib in Prurigo Spectrum Disorders: A Case Series.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prurigo simplex and prurigo nodularis are chronic, pruritic dermatoses with complex, cytokine-driven immunopathogenesis involving the JAK1-STAT signaling pathway. Real-world data on abrocitinib, a selective oral JAK1 inhibitor, in refractory pruritic dermatoses remain limited in the Indian population. Herein, we report four patients with prurigo spectrum disorders who were unresponsive to conventional therapies. Abrocitinib (100-200 mg once daily) resulted in rapid improvement in pruritus, followed by reduction in clinical lesions, including flattening of prurigo-like nodules, decreased pigmentation, and overall improvement in quality of life. No major adverse events were observed. These findings suggest that abrocitinib monotherapy may be an effective and well-tolerated option for refractory prurigo, warranting further evaluation in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.